Literature DB >> 16507758

N6-isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation.

Chiara Laezza1, Maria Notarnicola, Maria Gabriella Caruso, Caterina Messa, Marco Macchia, Simone Bertini, Filippo Minutolo, Giuseppe Portella, Laura Fiorentino, Stefania Stingo, Maurizio Bifulco.   

Abstract

The physiological effects of a variety of N6-substituted adenine and adenosine derivatives called cytokinins have been documented in plants, but information on their occurrence and function in other biological system is limited. Here we investigated the anti-proliferative effect of N6-isopentenyladenosine (i6A), an adenosine and isoprenoid derivative, in a thyroid cell system, FRTL-5 wild-type, and K-ras transformed KiMol cells. Addition of i6A to FRTL-5 cells caused a dose-dependent arrest of the G0-G1 cell phase transition associated with a reduction of cells in the S phase that was much more evident in KiMol cells. I6A arrested tumor cell proliferation by inhibiting farnesyl diphosphate synthase (FPPS) and protein prenylation. Indeed the addition of farnesol reversed these effects and i6A affected protein prenylation, in particular lamin B processing. I6A effect was not mediated by the adenosine receptor but was due to a direct modulation of FPPS enzyme activity as a result of its uptake inside the cells. I6A inhibited FPPS activity more efficaciously in KiMol cells than in normal FRTL-5. Moreover, the i6A anti-proliferative effect was evaluated in vivo in a nude mouse xenograft model, where KiMol cells were implanted subcutaneously. Mice treated with i6A showed a drastic reduction in tumor volume. Our findings indicate that this isoprenoid end product might be used for antineoplastic therapy, an application emulating that of the lovastatin and/or farnesyl-transferase inhibitors

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507758     DOI: 10.1096/fj.05-4044lsf

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  12 in total

1.  The isoprenoid derivative N6 -benzyladenosine CM223 exerts antitumor effects in glioma patient-derived primary cells through the mevalonate pathway.

Authors:  Elena Ciaglia; Manuela Grimaldi; Mario Abate; Mario Scrima; Manuela Rodriquez; Chiara Laezza; Roberta Ranieri; Simona Pisanti; Pierangela Ciuffreda; Clementina Manera; Patrizia Gazzerro; Anna Maria D'Ursi; Maurizio Bifulco
Journal:  Br J Pharmacol       Date:  2017-06-11       Impact factor: 8.739

Review 2.  Targeting prenylation inhibition through the mevalonate pathway.

Authors:  Pimyupa Manaswiyoungkul; Elvin D de Araujo; Patrick T Gunning
Journal:  RSC Med Chem       Date:  2019-12-23

3.  Snapshots of dynamics in synthesizing N(6)-isopentenyladenosine at the tRNA anticodon.

Authors:  Sarin Chimnaronk; Farhad Forouhar; Junichi Sakai; Min Yao; Cecile M Tron; Mohamed Atta; Marc Fontecave; John F Hunt; Isao Tanaka
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

4.  N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.

Authors:  Roberta Ranieri; Elena Ciaglia; Giuseppina Amodio; Paola Picardi; Maria Chiara Proto; Patrizia Gazzerro; Chiara Laezza; Paolo Remondelli; Maurizio Bifulco; Simona Pisanti
Journal:  Cell Death Differ       Date:  2017-10-13       Impact factor: 15.828

5.  N(6)-isopentenyladenosine and analogs activate the NRF2-mediated antioxidant response.

Authors:  Alice Dassano; Mariateresa Mancuso; Paola Giardullo; Loris De Cecco; Pierangela Ciuffreda; Enzo Santaniello; Anna Saran; Tommaso A Dragani; Francesca Colombo
Journal:  Redox Biol       Date:  2014-03-06       Impact factor: 11.799

6.  The isoprenoid end product N6-isopentenyladenosine reduces inflammatory response through the inhibition of the NFκB and STAT3 pathways in cystic fibrosis cells.

Authors:  Antonietta Santoro; Elena Ciaglia; Vanessa Nicolin; Alessandra Pescatore; Lucia Prota; Mario Capunzo; Matilde V Ursini; Stefania L Nori; Maurizio Bifulco
Journal:  Inflamm Res       Date:  2017-12-11       Impact factor: 4.575

7.  N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor.

Authors:  Donatella Fiore; Chiara Piscopo; Maria Chiara Proto; Michele Vasaturo; Fabrizio Dal Piaz; Bruno Marcello Fusco; Cristina Pagano; Chiara Laezza; Maurizio Bifulco; Patrizia Gazzerro
Journal:  Cancers (Basel)       Date:  2019-09-28       Impact factor: 6.639

8.  Towards an Improvement of Anticancer Activity of Benzyl Adenosine Analogs.

Authors:  Verdiana Covelli; Manuela Grimaldi; Rosario Randino; Mohammad Firoznezhad; Maria Chiara Proto; Veronica De Simone; Gianluca Matteoli; Patrizia Gazzerro; Maurizio Bifulco; Anna Maria D'Ursi; Manuela Rodriquez
Journal:  Molecules       Date:  2021-11-25       Impact factor: 4.411

9.  N6-isopentenyladenosine induces cell death through necroptosis in human glioblastoma cells.

Authors:  Cristina Pagano; Giovanna Navarra; Laura Coppola; Giorgio Avilia; Olga Pastorino; Rosa Della Monica; Michela Buonaiuto; Giovanni Torelli; Pasquale Caiazzo; Maurizio Bifulco; Chiara Laezza
Journal:  Cell Death Discov       Date:  2022-04-07

10.  Deregulated expression and activity of Farnesyl Diphosphate Synthase (FDPS) in Glioblastoma.

Authors:  Mario Abate; Chiara Laezza; Simona Pisanti; Giovanni Torelli; Vincenzo Seneca; Giuseppe Catapano; Francesco Montella; Roberta Ranieri; Maria Notarnicola; Patrizia Gazzerro; Maurizio Bifulco; Elena Ciaglia
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.